Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Selpercatinib (Retevmo) is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, medullary thyroid cancer, and other solid tumors that have a rearranged during transfection gene fusion. It is also used in pediatric patients 12 years and older who require systemic therapy.
• The information was derived from one systematic review/meta-analysis study which compared selpercatinib to pralsetinib, both FDA-approved RET-specific tyrosine kinase inhibitors.
• Both drugs demonstrated high effectiveness in inducing tumor responses with objective response rates ranging between 60% to 89%. However, complete eradication of the tumor was less common, as shown by lower complete response rates between 0% and 11%.
• Safety profiles showed grade three or higher adverse events reported in about a quarter to half of all treated patients. Common side effects included hypertension, altered liver enzymes (ALT changes), QT prolongation (a measure of altered heart rhythm), neutropenia (low white blood cell count), and pneumonitis (lung tissue inflammation).
• There were no direct comparative data provided on safety and efficacy between selpercatinib and pralsetinib, but their overlapping ranges suggest similar effectiveness. Their safety profiles also appeared comparable based on listed side effects.
• No specific details were given regarding population types or subgroup considerations such as age or gender. However, the indications for these drugs cover various RET-altered tumor types across different patient demographics, including adults and children aged over twelve, suggesting broad applicability.